

May 7, 1966

Dr. Craig D. Burrell
Sandoz Pharmaceuticals
Medical Department
Hanover, New Jersey 07936

Dear Dr. Burrell:

Following your letter of April 11, indicating that Sandoz Pharmaceuticals has withdrawn its IND for the studies of LSD, we have reviewed our records and the supplies available to us.

During the past two years, we have used LSD as a provocative therapeutic agent in the treatment of the severe, therapy resistant psychotics available in this Institution. We have also used this material for neurophysiological investigations. At present, we have available 175 ampules of LSD.

This study program has been under the direction of Dr. Turan Itil and myself, following our program sponsored by NIMH - MI-11381. He has been in contact with Dr. Jonathan Cole of the NIMH in Washington. Effective this date, I am transferring this supply of LSD to his control with the expectation that he will undertake such measures as may be necessary to continue the study program.

In addition, we had received in August 1964, LSD substance (100 mg) for Dr. Lang, a pharmacologist working in these laboratories. Dr. Lang left these laboratories last year and was soon followed by his supervisor, Dr. S. Gershon. At present, Dr. B. Korol has responsibility for the animal laboratories. I notified him of your request and he was able to account for one-half the supply only, and has delivered to me two vials, each marked LSD-25 substance - 25 mg with the code designation 160015. The records do not make clear the state of the remainder of the LSD substance. I have requested that he obtain an accounting from Dr. Gershon and I hope that this will be made available in the near future. In the meantime, I am sending you the two vials which have been given to me.

I will be in St. Louis until the first week in June, and thereafter can be reached at:

Max Fink, M.D.
Professor of Psychiatry
New York Medical College
Fifth Avenue at 106th Street
New York, New York 10029

Dr. Burrell

-2-

May 7, 1968

Thank you very much for your assistance in the various programs in which we have been able to collaborate during the days in Missouri. As I will be establishing similar clinical evaluation programs in New York, I trust we will be able to continue to collaborate.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp